Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer

European Journal of Gynaecological Oncology

Volumn 36, Issue 3, 2015, Pages 260-267

  Salmena, L ^a,b,c   Shaw, P ^d   Fan, I ^e   McLaughlin, J R ^e   Rosen, B ^f   Risch, H ^g   Mitchell, C ^h   Sun, P ^c   Narod, S A ^a,c   Kotsopoulos, J ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g YALE UNIVERSITY   (United States)

^h MONASH UNIVERSITY   (Australia)

Author keywords

INPP4B; Ovarian cancer; P53; Prognosis; PTEN; Survival.

Indexed keywords

INOSITOL POLYPHOSPHATE 4 PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYPHOSPHOINOSITIDE; PROTEIN P53; UNCLASSIFIED DRUG; PHOSPHATASE; PHOSPHATIDYLINOSITOL-3,4-BISPHOSPHATE 4-PHOSPHATASE; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANADA; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; ENDOMETRIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; ADENOCARCINOMA; CANCER STAGING; ENDOMETRIOID CARCINOMA; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CARCINOMA, ENDOMETRIOID; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84931067630     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: 10.12892/ejgo2741.2015     Document Type: Article

References (40)

1. Cannista SA.: "Cancer of the ovary". N Engl. J. Med, 2004,351,2519.
2. Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A.: "Ovarian cancer". Lancet, 2014, pii: S0140-6736(13)62146-7. doi: 10.1016/S0140-6736(13)62146-7. [Epub ahead of print]
3. Agarwal R., Kaye S.B.: "Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature reviews". Cancer, 2003,3,502.
4. Cantley L.C.: "The phosphoinositide 3-kinase pathway". Science, 2002,296,1655.
5. Cancer Genome Atlas Research Network: "Integrated genomic analyses of ovarian carcinoma". Nature, 2011, 474, 609. doi: 10.1038/na-turel0166.
6. Ranchi K.L., JohnsonKJ., Lu C, McLellanM.D., LeisersonM.D., Wendl M.C., et al.: "Integrated analysis of germline and somatic variants in ovarian cancer".Nature Commun., 2014,5,3156. doi: 10.1038/ncomms4156.
7. Zhang S., Royer R., Li S., McLaughlin J.R., Rosen B., Risch H.A., et al: "Frequencies of BRCA1 andBRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer". Gynecol. Oncol, 2011,121,353.
8. Fedele CG., Ooms L.M., Ho M., Vieusseux J., O'Toole S.A., Millar E.K., et al: "Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers". Proc. Natl. Acad. Sci. USA, 2010,107, 22231. doi: 10.1073/pnas. 1015245107. Epub 2010 Dec 2.
9. Norris F.A., Auethavekiat V., Majerus P.W.: "The isolation and characterization of cDNA encoding human and rat brain inositol polyphosphate 4-phosphatase". J. Biol. Chem., 1995,270,16128.
10. Johannsdottir H.K., Johannesdottir G., Agnarsson B.A., Eerola H., Arason A., Johannsson O.T., et al.: "Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables". Anticancer Res., 2004,24,2681.
11. Westbrook T.F., Martin E.S., Schlabach M.R., Leng Y., Liang A.C., Feng B., et al: "A genetic screen for candidate tumor suppressors identifies REST". Cell, 2005,121, 837.
12. Agoulnik I.U., Hodgson M.C., Bowden W.A., Ittmann M.M.: "INPP4B: the new kid on the PI3K block". Oncotarget, 2011,2,321.
13. Bergamaschi A., Kim Y.H., Wang P., Sorlie T., Hernandez-Boussard T., Lonning P.E., et al: "Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer". Genes Chromosomes Cancer, 2006, 45, 1033.
14. Gewinner C, Wang Z.C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., et al: "Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling". Cancer Cell, 2009,16,115.
15. Michalovitz D., Halevy O., Oren M.: "p53 mutations: gains or losses?" J. Cell Biochem., 1991,45,22.
16. Singh B., Reddy P.G., Goberdhan A., Walsh C, Dao S., Ngai I., et al: "p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas". Genes Dev., 2002,16, 984.
17. de GraefFP., Crijns A.P., de Jong S., Boezen M., Post W.J., de Vries E.G., et al: "Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis". Br. J. Cancer, 2009,101, 149.
18. Landen C.N. Jr., Birrer M.J., Sood A.K.: "Early events in the pathogenesis of epithelial ovarian cancer". J. Clin. Oncol, 2008,26,995.
19. Kmet L.M., Cook L.S., Magliocco A.M.: "A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors". Cancer, 2003,97,389.
20. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R., et al: "Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary". J. Pathol, 2010,221,49.
21. Kuhn E., Kurman R.J., Vang R., Sehdev A.S., Han G., Soslow R., et al: "TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions". J. Pathol, 2012,226,421.
22. Salmena L., Carracedo A., Pandolfi P.P.: "Tenets of PTEN tumor suppression". Cell, 2008,133,403.
23. Ali LU., Schriml L.M., Dean M.: "Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity". J. Natl. Cancer Inst., 1999,91,1922.
24. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix-Trench G., Thomas E.J., Campbell I.G.: "Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors". Cancer Res., 1998,58,2095.
25. Jarboe E.A., Folkins A.K., Drapkin R., Ince T.A., Agoston E.S., Crum CP.: "Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective". Histopathology, 2008,53, 127.
26. Djordjevic B., Hennessy B.T., Li J., Barkoh B.A., Luthra R., Mills G.B., Broaddus R.R.: "Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing". Mod. Pathol, 2012,25,699.
27. Mutter G.L., Ince T.A., Baak J.P., Kust G.A., Zhou X.P., Eng C: "Molecular identification of latent precancers in histologically normal endometrium". Cancer Res., 2001, 61,4311.
28. Ali-Fehmi R., Khalifeh I., Bandyopadhyay S., Lawrence W.D., Silva E., Liao D., et al: "Patterns of loss of heterozygosity at 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis, and ovarian carcinoma arising in association with endometriosis". Int. J. Gynecol. Pathol, 2006,25,223.
29. Obata K., Hoshiai H.: "Common genetic changes between endometriosis and ovarian cancer". Gynecol. Obstet. Invest., 2000,50, 39.
30. Sato N., Tsunoda H., Nishida M., Morishita Y., Takimoto Y., Kubo T., Noguchi MX: "Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary". Cancer Res., 2000, 60,7052.
31. Saito M., Okamoto A., Kohno T., Takakura S., Shinozaki H., Ison-ishi S., et al: "Allelic imbalance and mutations of the PTEN gene in ovarian cancer". Int. J. Cancer, 2000,85,160.
32. Davidson B., Hadar R., Schlossberg A., Sternlicht T., Slipicevic A., Skrede M.,etal: "Expression and clinical role of D J-1, a negative regulator of PTEN, in ovarian carcinoma". Hum. Pathol, 2008,39,87.
33. Wang Y., Kristensen G.B., Heiland A., Nesland J.M., Borresen-Dale A.L., Holm R.: "Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas". Am. J. Clin. Pathol, 2005,124,392.
34. Abe A., Minaguchi T., Ochi H., Onuki M., Okada S., Matsumoto K., et al: "PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma". Hum. Pathol, 2013,44,199.
35. Skirnisdottir I., Seidal T.: "Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer". Int. J. Gynecol. Cancer, 2011,21,1024.
36. Schondorf T., Gohring U.J., Roth G., Middel I., Becker M., Moser N.V., et al: "Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients". Eur. J. Clin. Invest., 2003,33,256.
37. Lee Y.K., Park N.H.: "Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers". Gynecol Oncol.,2009,112,475.
38. de Graeff P., Crijns A.P., Ten Hoor K.A., Klip H.G., Hollema H., Oien K., et al: "The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer". Br. J. Cancer, 2008,99,341.
39. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., Eng C: "Frequent loss of PTEN expression is linked to elevated phosphory-lated Akt levels, but not associated with p27 and cyclin Dl expression, in primary epithelial ovarian carcinomas". Am. J. Pathol, 2001, 158,2097.
40. Risinger J.I., Hayes K., Maxwell G.L., Carney M.E., Dodge R.K., Barrett J.C., Berchuck A.: "PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics". Clin. Cancer Res., 1998,4, 3005.